Dianthus Therapeutics, Inc.
DNTH
Rank in Stocks
#3773
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Share Price
$79.23
Last synced: 2026-10-20
Market Cap
$4.43B
Change (1 day)
6.29%
Change (1 year)
126.18%
Country
US
Trade Dianthus Therapeutics, Inc. (DNTH)
Category
Healthcare
Stock price history for Dianthus Therapeutics, Inc. (DNTH)
Highest end of day price: $81.00 on 2026-10-01
Lowest end of day price: $225.69 on 2018-06-01
Lowest end of day price: $225.69 on 2018-06-01
Stock price history of Dianthus Therapeutics, Inc. from 2018 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 74.00% |
| 2025 | 79.27% |
| 2024 | 158.65% |
| 2023 | -30.65% |
| 2022 | -83.63% |
| 2021 | -32.46% |
| 2020 | -46.40% |
| 2019 | 100.40% |
| 2018 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $514.04 | 20.59% |
US
|
|
| $241.53 | 778.61% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $813.37 | 16.03% |
CH
|
|
| $875.26 | 4.85% |
NL
|
